Multi-psychotropic drug prescription and the association to neuropsychiatric symptoms in three Norwegian nursing home cohorts between 2004 and 2011

Christine Gulla1*, Geir Selbaek2,3,4, Elisabeth Flo1, Reidun Kjome5,8, Øyvind Kirkevold2,3,6,9 and Bettina S. Husebo1,7

Abstract

Background: Neuropsychiatric symptoms, such as affective symptoms, psychosis, agitation, and apathy are common among nursing home patients with and without dementia. Treatment with one or more psychotropic drug is often without explicit clinical indication, despite low treatment efficacy, and potential side effects. We aim to investigate the multi-psychotropic drug use to identify factors and patient characteristics associated with multi-use.

Methods: We analysed three cohorts from 129 Norwegian nursing homes, collected between 2004 and 2011. Patients (N = 4739) were assessed with the Neuropsychiatric Inventory – Nursing Home version (NPI-NH), Clinical Dementia Rating scale, and Physical Self Maintenance Scale. We used ordinal logistic regression to analyse associations between psychotropics (antidepressants, antipsychotics, anxiolytics, hypnotics, and anti-dementia drugs), patient characteristics, and neuropsychiatric symptoms.

Results: Patients used on average 6.6 drugs; 27 % used no psychotropics, 32 % one, and 41 % multiple psychotropic drugs (24 % two, 17 % ≥3). Thirty-nine percent were prescribed antidepressants, 30 % sedatives, 24 % anxiolytics, and 20 % antipsychotics. The total NPI-NH score was associated with multi-use (OR 1.02, 95 % CI 1.02–1.03), and increased from a mean of 13.5 (SD 16.3) for patients using none, to 25.5 (21.8) for patients using ≥3 psychotropics. Affective symptoms (depression and anxiety) were most strongly associated with multi-psychotropic drug use (OR 1.10, 95 % CI: 1.09–1.12). Female gender, independency in daily living, younger age, dementia, and many regular drugs were also associated with multi-use.

Conclusion: Forty-one percent were exposed to multi-psychotropic drug prescriptions. Contrary to current evidence and guidelines, there is an extensive use of multiple psychotropic drugs in patients with severe NPS and dementia.

Keywords: Dementia, Nursing homes, Neuropsychiatric symptoms, Psychotropic drugs, Antidepressants, Antipsychotics, Hypnotics, Anxiolytics, Anti-dementia drugs

Background

Neuropsychiatric symptoms (NPS), such as agitation, psychosis, depression, anxiety, and sleep problems, are frequently observed among nursing home (NH) patients with and without dementia [1, 2]. Approximately 90 % of all people with dementia experience NPS during the course of the disease [2]. These symptoms are distressing for the patient, the relatives, and the caregivers [3]. People with dementia and NPS are often treated with psychotropic drugs [4], despite national and international warnings concerning severe side effects [5, 6]. Recent prevalence rates reflected widespread use; for example, Nijk et al. investigated psychotropic drug use in 1322 NH patients from 59 dementia care units in the Netherlands [7]. Psychotropic drugs were used by 63 % of the patients, 20 % used two, and 7 % used three or more. Antipsychotics were the most prevalent of the

* Correspondence: christine.gulla@uib.no
1 Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, PO Box 7804N-5018 Bergen, Norway
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Psychotropic drugs are often prescribed without proper symptom assessment, without any clear indications, and treatment persists for longer than recommended [10]. In addition, review articles investigating the benefit of psychotropic drugs on NPS found minor to no treatment effects [4, 11, 12]. Two reviews on the discontinuation of psychotropics in older adults demonstrated that discontinuation decreased the incidence of falls and delirium, and the NPS remained stable [13, 14]. A randomized placebo controlled trial on discontinuation of antidepressants in nursing home patients found that 86% could discontinue successfully, however there was increased depressive symptoms in the intervention group compared to the controls [15]. Another randomized placebo controlled trial on the effect of sertraline in major depressive episodes in patients with Alzheimer disease, found that sertraline was superior to placebo in treating major depressive disorders [16]. These studies indicate an effect of antidepressants given the right indication is present, and the importance of weighting potential benefit to harm.

Treatment safety is another important factor because increased mortality rates were found for people with dementia using atypical antipsychotics [17]. The antipsychotic withdrawal trial (DART-AD) on Alzheimer’s patients from NHs in the UK even showed that survival for the discontinuation group was not only higher after 12 months, but the difference in survival increased with time [18]. Increased mortality, and adverse events such as falls, stroke, and fractures have also been related to antidepressants; serious side effects were even more prevalent for selective serotonin reuptake inhibitors compared to tricyclic antidepressants [19]. Another population-based study (N = 906 422) showed an increased risk of hip-fractures in users of hypnotics and anxiolytics [20].

Despite the considerable focus on psychotropic use in general, little attention has been given to multi-psychotropics and benzodiazepine hypnotics. The use of two different psychotropics increased from 17 to 22% and three different drugs from 5 to 11%.

Psychotropic drugs are often prescribed without proper symptom assessment, without any clear indications, and treatment persists for longer than recommended [10]. In addition, review articles investigating the benefit of psychotropic drugs on NPS found minor to no treatment effects [4, 11, 12]. Two reviews on the discontinuation of psychotropics in older adults demonstrated that discontinuation decreased the incidence of falls and delirium, and the NPS remained stable [13, 14]. A randomized placebo controlled trial on discontinuation of antidepressants in nursing home patients found that 86% could discontinue successfully, however there was increased depressive symptoms in the intervention group compared to the controls [15]. Another randomized placebo controlled trial on the effect of sertraline in major depressive episodes in patients with Alzheimer disease, found that sertraline was superior to placebo in treating major depressive disorders [16]. These studies indicate an effect of antidepressants given the right indication is present, and the importance of weighting potential benefit to harm.

Method

Subjects

We included patients, 65 years and older, from three Norwegian cross-sectional multi-centre NH studies from 2004, 2007, and 2011. Norwegian NHs are managed by the municipalities and are an essential part of the primary health care system. All patients in the included wards were eligible if they had lived in the NH for more than 2 weeks prior to data collection and consented to participate. Demographics, diagnoses and information on prescribed medicines were collected from the patients’ medical records. Standardized interviews of nurses, who knew the patients well, were used to collect data on clinical status.

The 2004 cohort included patients in 26 NHs from 18 municipalities in four counties, 1165 patients were eligible, two declined to participate, and 26 were too young, giving a total of 1137 patients. Data was originally collected to explore the association between NPS and psychotropic drug use at different stages of dementia [21]. Before data collection, registered nurses were trained during a 2-day programme on structured interviews for primary caregivers.

The 2007 cohort examined patients living in 63 NHs in the South-Eastern health region of Norway. In all, 151 wards were included, with 2108 eligible patients, 162 had a stay less than 2 weeks, 3 declined to participate, and 64 were too young, giving 1879 patients in total. This study investigated the problematic practice of withholding medication to patients by concealing them in food and beverages [22]. Registered nurses received 2 h of training in addition to oral and written instructions on how to complete data collection. This study did not collect data on diagnoses.

The 2011 cohort consisted of 23 of the 26 NHs, which were included in the 2004 cohort, along with 40 new NHs from 31 municipalities altogether. For patients assessed in both 2004 and 2011, we used only data from 2004. Altogether, 2385 patients were eligible, 98 were also assessed in 2004, 423 declined to participate, 17 died before assessment, 33 were terminally ill or had a serious somatic condition, one moved, 53 were excluded without giving a cause, and 37 were too young, giving
1723 patients. The 2004 procedure for inclusion, education and collection of data was used [23].

Outcome measures
The Neuropsychiatric Inventory – NH version (NPI –NH) is a 12-item proxy rated instrument to assess the frequency and severity of NPS over the last 4 weeks in people with and without dementia [24]. NPI-NH consists of items for delusions, hallucination, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, night-time behaviour, and eating disturbances. Items are scored on frequency (0 to 4 – absent to daily) and severity for the patient (1 to 3 – mild to severe). Severity and frequency are multiplied to create a sum-score from 0 to 12 for each item. The Norwegian translation has good validity and reliability [25]. In this study, items were clustered into the clinical relevant sub-syndromes, following a previous exploratory factor analysis, psychosis (hallucination and delusions), affective symptoms (depression and anxiety), and agitation (agitation and irritability). Apathy did not cluster with any of the sub-syndromes [26].

The Clinical Dementia Rating Scale (CDR) assesses the level of dementia [27, 28]. The CDR score is calculated with an algorithm giving extra weight to memory problems. CDR scores of 0, 0.5, 1, 2, and 3, indicate no, possible, mild, moderate, and severe dementia, respectively. In the 2007 cohort CDR 0.5 was scored as 0.

The patients’ dependency in daily living was measured with the Physical Self-Maintenance Scale (PSMS). The six items toileting, feeding, dressing, grooming, physical ambulation, and bathing yield an aggregate score of 6–30; higher scores indicate higher dependency in activities of daily living. Good reliability and validity of PSMS has been reported earlier [29, 30].

Medication and diagnoses
The psychotropic drugs were classified as antipsychotics (N05A), anxiolytics (N05B), sedatives (N05C), antidepressants (N06A), and anti-dementia drugs (N06D) in the Anatomical Therapeutic Chemical Index (ATC) classes [31]. “Regular drugs” was a count of the drugs the patient was prescribed on the day of data collection, pro re nata drugs were not included in this count. “Regular drugs without psychotropics” was the number of regular drugs, when psychotropic drugs were subtracted. The diagnoses were coded with International Classification of Diseases – 10th version [32]. Dementia is an aggregate of the diagnoses F00 dementia with Alzheimer, F01 vascular dementia, F02 dementia in other diseases classified elsewhere, and F03 unspecified dementia.

Statistical methods
Background characteristics and comparisons between the cohorts were analysed using chi-square for categorical variables, and one-way ANOVA for continuous variables. The total NPI-NH score was log-transformed in the ANOVA due to non-normality. Association between CDR and dementia was tested using chi square test and Phi for strength of association. The patients were divided into four ordinal groups according to number of psychotropic prescriptions (0, 1, 2 and ≥3). We used cumulative odds ordinal logistic regression with proportional odds analyses [33] to create odds ratios (OR), 95 % confidence intervals (CI), and p-values for the association between the prescription of psychotropic drugs and age, gender, severity of dementia, NPS, dependency in activities of daily living, regular drugs without psychotropics, and diagnoses. We created two logistic regression analyses (Analysis 1 and 2) because the 2007 cohort did not contain information on

Table 1 Demographics of the study population in total and by cohort

|                          | Total          | 2004 N = 1137 | 2007 N = 1879 | 2011 N = 1723 | P-value |
|--------------------------|----------------|--------------|--------------|--------------|---------|
| Age, mean (SD) a,b        | 85.7 (7.0)     | 85.0 (6.5)   | 85.9 (7.1)   | 85.9 (7.1)   | 0.03    |
| Women, N (%)              | 3383 (71)      | 836 (16)     | 1321 (70)    | 1226 (71)    | NS      |
| Regular drugs without psychotropics, mean (SD) a,b,c | 5.2 (2.9)  | 4.7 (2.8)  | 5.1 (2.9)  | 5.7 (3.0)  | <0.001 |
| Dementia (CDR), N (%)     |                |              |              |              |         |
| No                       | 497 (11)       | 37 (3)       | 406 (22)     | 54 (3)       | <0.001  |
| Questionable             | 388 (8)        | 183 (16)     | 0 (0)        | 205 (12)     |         |
| Mild                     | 686 (15)       | 225 (20)     | 163 (9)      | 298 (18)     |         |
| Moderate                 | 1336 (28)      | 306 (27)     | 529 (28)     | 501 (30)     |         |
| Severe                   | 1786 (38)      | 382 (34)     | 768 (41)     | 636 (38)     |         |
| Dependency, mean (SD) a,d | 18.1 (5.4)     | 18.0 (5.3)   | 18.5 (5.5)   | 17.7 (5.3)   | <0.001  |
| NPI-NH total score, mean (SD) | 17.5 (18.7) | 18.5 (19.2) | 16.1 (17.6) | 18.5 (17.6) | 0.03 |

ANOVA for continuous and X² for categorical data
NPI-NH neuropsychiatric inventory – nursing home version, SD standard deviation, NS not significant
CDR Clinical Dementia Rating scale 1 to 3, aSignificant between 2004 and 2007, bSignificant between 2004 and 2011, cSignificant between 2007 and 2011, dHigher scores indicates more dependency in daily living
diagnoses and NPS-NH total score and the sub-syndromes can cause a potential multicollinearity problem. Both regression analyses included age, gender, regular drugs without psychotropics, dependency, and cohort. Analysis 1 also contained severity of dementia measured by CDR and the sub-syndromes of NPS (affective symptoms, agitation, psychosis, and apathy). Analysis 2 covered the NPI-NH total score and the most frequent diagnoses. We adjusted for cohort year in the analyses due to differences in the demographics between the cohorts; the cohort was included as a nominal independent variable (2011 as reference). Both analyses met the assumption of proportional odds and there was no multicollinearity. Statistical significance was set to $p < 0.05$. IBM SPSS statistics version 22.0 (IBM Corp, Armonk, NY, USA) was used to perform the analyses.

**Results**

In total, 4739 participants were included from three cohorts of 129 Norwegian NHs, assessed in 2004, 2007, and 2011. Demographics and clinical characteristics stratified by cohort-year are shown in Table 1. The mean

### Table 2 Clinical characteristics associated with psychotropic drug use, crude and adjusted values for Analysis 1 and 2

| Psychotropic drugs | Crude | Adjusted |
|--------------------|-------|----------|
| 0                  | 1     | 2        | 3       | 0.97** | 0.96–0.98 | 0.97** | 0.96–0.98 |
| Patients, %         | 27.3  | 32.2     | 23.4    | 17.1    |
| Factors included in Analyses 1 and 2 |
| Age, mean (SD)      | 88.7  | 86.1     | 85.3    | 83.9    | 0.97** | 1.01–1.27 | 1.06–1.36 |
| Females, %          | 68.8  | 72.4     | 72.5    | 72.8    | 1.13   | 1.01–1.27 | 1.06–1.36 |
| Dependency, mean (SD) | 18.9   | 18.1     | 17.8    | 17.2    | 0.97** | 0.96–0.98 | 0.96** | 0.95–0.97 |
| Regular drugs without psychotropics, mean (SD) | 4.9 (2.8) | 5.3 (3.0) | 5.5 (2.9) | 5.2 (2.9) | 1.04** | 1.02–1.06 | 1.05** | 1.03–1.07 |

#### Analysis 1

**Cognitive impairment**

| No, %         | 9.9  | 11.1 | 11.0 | 10.3 | 1 | 1 |
| Questionable, % | 9.2  | 7.7  | 8.2  | 8.0  | 0.88 | 0.70–1.12 | 1.19 | 0.91–1.55 |
| Mild, %       | 13.3 | 15.6 | 14.1 | 15.7 | 1.03 | 0.84–1.27 | 1.23 | 0.98–1.54 |
| Moderate, %   | 26.0 | 28.6 | 31.1 | 28.5 | 1.05 | 0.87–1.26 | 1.19 | 0.97–1.46 |
| Severe, %     | 41.6 | 37.1 | 35.7 | 37.6 | 0.89 | 0.74–1.06 | 1.15 | 0.92–1.42 |

**NPI-NH sub-syndromes**

| Affective symptoms, mean (SD) | 1.8 (3.5) | 2.6 (4.2) | 3.9 (5.2) | 5.9 (6.2) | 1.10–1.13 | 1.10** | 1.09–1.12 |
| Agitation, mean (SD)          | 3.2 (5.2) | 3.5 (5.5) | 4.4 (6.1) | 5.7 (6.5) | 1.04–1.06 | 1.05** | 1.01–1.03 |
| Psychosis, mean (SD)          | 1.8 (4.1) | 2.3 (4.6) | 2.8 (5.0) | 4.4 (6.3) | 1.05–1.07 | 1.05** | 1.01–1.04 |
| Apathy, mean (SD)             | 1.9 (3.5) | 1.8 (3.2) | 2.0 (3.4) | 2.3 (3.6) | 1.00–1.03 | 0.99 | 0.98–1.01 |

#### Analysis 2, 2004 and 2011 cohort

| NPI-NH total score | 13.5 (16.3) | 15.4 (16.8) | 19.2 (19.3) | 25.5 (21.8) | 1.02** | 1.02–1.02 | 1.02** | 1.02–1.03 |

**Diagnoses**

| Dementia, %         | 27.4  | 26.9 | 26.5 | 33.3 | 1.13** | 1.01–1.27 | 1.19** | 1.03–1.37 |
| Hypertension, %     | 14.4  | 13.5 | 14.2 | 12.4 | 0.93  | 0.81–1.08 | 1.01 | 0.86–1.19 |
| Stroke, %           | 12.2  | 9.3  | 9.2  | 7.3  | 0.72** | 0.61–0.86 | 0.89 | 0.74–1.07 |
| Heart failure, %    | 9.3   | 7.8  | 7.3  | 7.0  | 0.82** | 0.68–0.99 | 0.90 | 0.73–1.11 |
| Atrial fibrillation/flutter, % | 8.5   | 8.3  | 6.8  | 5.7  | 0.78** | 0.64–0.94 | 0.92 | 0.75–1.13 |
| Angina, %           | 3.9   | 4.7  | 6.1  | 6.1  | 1.42** | 1.13–1.79 | 1.60** | 1.26–2.04 |
| Osteoporosis, %     | 5.7   | 6.0  | 4.7  | 4.8  | 0.85  | 0.68–1.08 | 0.91 | 0.72–1.16 |
| Hip fracture, %     | 6.1   | 5.0  | 4.8  | 5.3  | 0.88  | 0.70–1.10 | 1.04 | 0.82–1.33 |
| Diabetes, %         | 5.8   | 5.2  | 5.4  | 2.8  | 0.75** | 0.59–0.95 | 0.75** | 0.59–0.97 |

*P*-values, odds ratios and confidence intervals from cumulative odds logistic regression. Analysis 1 and 2 included age, sex, dependency and total medication. The factor unique to each analysis is listed below their headlines in the table.

NPI-NH neuropsychiatric inventory – nursing home version, SD standard deviation, OR odds ratio, CI confidence interval

*used as reference, †assessed by Clinical Dementia Rating scale, ‡from ICD-codes in patient records, ‡‡p-value < 0.05, ‡‡‡p-value < 0.001, ‡‡‡‡higher scores indicates more dependency in daily living.
age was 86 years; 71 % of the patients were women, and they used on average 6.6 drugs. Age ($p = 0.03$) and regular drugs ($p < 0.001$) differed significantly between the cohorts, with higher age and more drugs in 2011. Dementia (46 %), hypertension (23 %), stroke (16 %), heart failure (13 %), atrial fibrillation (13 %), osteoporosis (9 %), hip fracture (9 %), angina (9 %), and diabetes (8 %) were the most frequent diagnoses in the medical records. Assessed by CDR, 80 % of the patients had dementia (CDR $\geq 1$). There was a small ($\Phi = 0.274$), but statistically significant ($p < 0.001$) association between dementia according to CDR and a diagnosis of dementia in the patient records. CDR identified 1307 (98 %) of the patients with a diagnosis of dementia in the records ($N = 1328$). Of the patients with no recorded diagnosis of dementia ($N = 3411$), 2547 (75 %) were classified with dementia according to CDR. The mean (SD) PSMS and NPI-NH scores were 18.1 (5.4) and 17.5 (18.7), respectively. Dementia, dependency and NPI-NH total score differed between the cohorts ($p < 0.05$), with more dementia and lower dependency in 2011, and lower NPI-NH score in 2007 (Table 1).

### Psychotropic drug use

Almost three out of four received at least one psychotropic drug and two out of five received two or more (range 0–7) (Table 2). Thirty-nine percent received antidepressants, 30 % sedatives, 24 % anxiolytics, 20 % antipsychotics, and 14 % anti-dementia drugs. The most frequent psychotropic drug combinations were antidepressants and sedatives (14 %), antidepressants and anxiolytics (12 %), and sedatives and anxiolytics (11 %). The most prescribed individual drug was the $z$-hypnotic, zopiclone (23 %). This medication was combined with oxazepam in 6 % of the patients, and with escitalopram in 4 % (Table 3).

### Factors associated with multi-psychotropic drug use

The total NPI-NH score was associated with multi-use (OR 1.02, 95 % CI 1.02–1.03), and increased from a mean of 13.5 (SD 16.3) for patients using none, to 25.5 (SD 21.8) for patients using $\geq 3$ psychotropics (Table 2). The sub-syndromes affective symptoms (OR 1.10, 95 % CI 1.09–1.12), agitation (OR 1.02, 95 % CI 1.01–1.03), and psychosis (OR 1.02, 95 % CI 1.01–1.04) demonstrated a significant association as well (Fig. 1). The adjusted OR for variables included in both Analysis 1 and 2 were similar and had the same effects; the OR listed here are from Analysis 1. Female gender (OR 1.20, 95 % CI 1.06–1.36), independency in daily activities (OR 0.96, 95 % CI 0.95–0.97), younger age (OR 0.97, 95 % CI 0.96–0.98), and more regular drugs without psychotropics (OR 1.05, 95 % CI 1.03–1.07) were all associated with increased psychotropic drug use. Compared to no diagnosis of dementia in their records (Analysis 2), having dementia increased the likelihood of being treated with multiple psychotropics (OR 1.19, 95 % CI 1.03–1.37) (Table 2). Poorer cognitive function measured with CDR was not associated with the use of psychotropics compared to normal cognitive function (Fig. 2). Of the other frequent diagnoses, diabetes lead to less psychotropics (OR 0.75, 95 % CI 0.59–0.97), while angina lead to more (OR 1.60, 95 % CI 1.26–2.04) (Table 2). The 2004 and 2007 had significantly higher risk of multi-use than the

### Table 3 Use of psychotropic drug groups, individual psychotropics, and combinations of psychotropics

| ATC code and generic name | N = 4739, % |
|---------------------------|-------------|
| N05A Antipsychotics       | 19.9        |
| N05A X08 Risperidone      | 5.6         |
| N05A D01 Haloperidol      | 3.4         |
| N05A H03 Olanzapine       | 2.8         |
| N05B Anxiolytics          | 23.9        |
| N05B A04 Oxazepam         | 19.2        |
| N05B B01 Hydroxyzine      | 3.2         |
| N05B A01 Diazepam         | 2.1         |
| N05C Sedatives            | 30.5        |
| N05C F01 Zopiclone        | 23.0        |
| N05C D02 Nitrazepam       | 3.4         |
| N05C M02 Clomethiazole    | 2.7         |
| N06A Antidepressants      | 39.2        |
| N06A B10 Escitalopram     | 12.5        |
| N06A B04 Citalopram       | 10.7        |
| N06A X03 Mianserin        | 7.4         |
| N06D Anti-dementia drugs  | 13.7        |
| N06D A02 Donepezil        | 6.8         |
| N06D X01 Memantine        | 4.7         |
| N06D A03 Rivastigmine     | 2.0         |
| Combinations of psychotropic drug classes |            |
| Antidepressants and sedatives | 14.4   |
| Antidepressants and anxiolytics | 12.1  |
| Sedatives and anxiolytics | 10.6        |
| Antidepressants and antipsychotics | 9.1     |
| Two antidepressants       | 6.2         |
| Combination of specific psychotropic drugs |            |
| Zopiclone and Oxazepam    | 5.6         |
| Zopiclone and Escitalopram| 3.5         |
| Zopiclone and Citalopram  | 3.3         |
| Oxazepam and Citalopram   | 3.0         |
| Oxazepam and Citalopram   | 2.8         |
| Oxazepam and Mianserin    | 2.5         |
| Zopiclone and Mianserin   | 2.2         |
2011 cohort, with the highest OR for the 2007 cohort (OR 1.65, 95 % CI 1.45–1.89).

**Discussion**

The present study found that 41 % of Norwegian NH patients were treated with two or more psychotropic drugs. Antidepressants (39 %) were most prevalent and often combined with sedatives (14 %) and anxiolytics (12 %). In accordance with our hypotheses, patients with severe NPS, especially depression and anxiety, used more psychotropics. Female gender, independency in daily activities, younger age, dementia, and more regular drugs, were all associated with multi-use.

High prevalence of multiple psychotropic drug use was also demonstrated by other NH studies. In a Dutch study, 27 % used two or more psychotropic drugs, and antipsychotics were the most prescribed drugs (37 %) [7]. An American study found that 45 % used two or more psychotropics, and antidepressants were most frequently used (41 %) [34]. A study from Sweden found that 28 % used ≥3 psychotropics, and 51 % used hypnotics [35].

The association between psychotropic drug use and NPS has been highlighted earlier [7, 36, 37]. This was supported by our study; we found that severe NPS, especially affective symptoms and agitation, were related to multi-use. The use of multiple psychotropic drugs might indicate that clinicians try to treat a symptom with one drug, and if the symptom persists, they add another drug, often with the same indication, without stopping or re-evaluating the treatment. This can be due to belief in the additive effect, or to the burden NPS puts on patients and caregivers, resulting in a pressure from caregivers to prescribe [37, 38]. The OR for the NPI items were low, for instance for affective symptoms it was 1.10. This reflects an increase of 10 % in odds of receiving more psychotropics for every unit change on the NPI-NH score. This implies that patients with severe symptoms received considerably more psychotropics.

The current study found that especially patients with depression and anxiety used more psychotropics. Indication for the drugs and appropriateness of their use is beyond the scope of this article. However, both depression and anxiety are prevalent among NH residents, and drugs for these conditions are commonly prescribed [39]. A recent study showed that the antidepressants were prescribed for other indications than depression in 50 % of the cases, and most patients lacked a diagnostic work-up [40]. Affective symptoms may have many causes, hence the assessment and treatment should be adjusted accordingly to avoid over-prescribing of psychotropics [41]. We also found independency in daily living to be associated with the use of more psychotropics. A possible reason for this could be that patients with high dependency are often bedridden or so reduced that they are incapable of causing the same level of commotion and staff.
distress as the mobile and active independent patients. Hence, the independent patients receive more psychotropics to dampen their symptoms, which might explain this association. Other studies show divergent associations [34, 36, 42].

Our results showed that people with a diagnosis of dementia in their records use more psychotropics than those without a diagnosis, despite the consensus that they should be treated with utmost caution and less psychotropic drugs [41, 43, 44]. An article describing the 2004 cohort found that only 55% of patients with dementia according to the CDR had a dementia diagnosis in the medical records in the nursing home [21]. The weak association between a dementia diagnosis and psychotropics might be an effect of staff blaming the dementia for the NPS, rather than investigation other causes for these symptoms [12]. Patients with a diagnosis of diabetes used fewer psychotropic drugs. This corroborates and extends earlier research that people with a high Charlson’s Comorbidity Score received fewer antipsychotics [45].

Limitations and strengths

There are some limitations to this study. Indications, duration, or doses were not recorded, nor were pro re nata medications. These factors, and the cross-sectional design, made it impossible to assess the appropriateness and effects of the drugs. We did not know whether the patient used the drugs because of severe NPS, if the NPS was reduced by the drugs, or the drugs aggravated NPS.

Another limitation is that the diagnoses listed in the medical records may be of low quality because of the absence of a standard of what to report and of sub-optimal electronic patient records [46]. The use of popular, validated and reliable assessment scales for NPS, dementia and ADL [24, 25, 27–30], are a major strength and make our results comparable to other studies. Age, percentage of women, drug use, and CDR scores were similar to other Norwegian nursing home studies [40, 47, 48]. The large cohort size, including patients from 129 NHs all over the country, from small and large municipalities, thus very likely mirrors the Norwegian NH population.

Conclusion

Forty-one percent of NH patients use multiple psychotropic drugs. Severe NPS, especially affective symptoms, were associated with extensive use. The use of multiple psychotropic drugs in in patients with dementia is widespread, contrary to current evidence and guidelines. There is an urgent need to test and implement methods to optimize prescription procedures for these patients.

Abbreviations

ATC, anatomical therapeutic chemical index; CDR, clinical dementia rating scale; CI, confidence intervals; ICD-10, international classification of diseases 10th version; NDPA, the Norwegian data protection authority; NH, nursing home; NPI-NH, the neuropsychiatric inventory – nursing home version; NPS, neuropsychiatric symptoms; OR, odds ratio; PSMS, physical self maintenance scale; REC-SE/E, the regional committees for medical and health research ethics: South-East and East; SD, standard deviation; SHDir, the directorate for health and social affairs.
Acknowledgements
BSH would like to thank the Norwegian Government and the GC Rieber Foundation for supporting her time for this work.

Funding
CG receives a PhD grant from the Research Council of Norway (Sponsor's Protocol Code: 222113/H10). The founding body had no role in the design of the study, data collection, analyses, interpretation of the data, or writing the manuscript.

Availability of data and materials
Data files are not available due to patient confidentiality.

Authors’ contributions
BSH, EF, RK and CG designed the study. CG conducted the analyses and drafted the manuscript. GS and OK drafted the initial studies and participated in data collection. All authors participated in preparation and finalisation of the manuscript. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
By law, in 2004, explicit consent was not required for participation, however, patients were informed that they could actively decline participation. In 2007, explicit consent was not required for participation due to the anonymity of the data, and patients could actively decline participation. No patients or relatives were interviewed, and the patients were only identified by sex and year of birth, hence the data was considered anonymous. For the 2011 cohort, the Norwegian law had changed, so informed consent was obtained from the patient. If the patient was unable to give an informed consent, the next of kin could give a presumed informed consent on the patient’s behalf. The Regional Committees for Medical and Health Research Ethics, South-East and East (REC-SE/E), the Norwegian Data Protection Authority (NDPA), and the Directorate for Health and Social Affairs (ShDir) approved the studies prior to initiation. 2004: REC-E ref 04/001, NDPA 10585, 2007: REC-SE ref 2006/002146-5/AY/400, NDPA ref 14524, ShDir ref 06/2636, 2011: REC-SE ref 2010/1984.

Author details
1Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, PO Box 7804N-5018 Bergen, Norway. 2Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, PO Box 2136N-3103 Tønsberg, Ottestad, Norway. 3Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway. 4Faculty of Medicine, Institute of Health and Society, University of Oslo, Oslo, Norway. 5Research group in Social Pharmacy, Department of Global Public Health and Primary Care, Centre for Pharmacy, University of Bergen, Bergen, Norway. 6Faculty of Health, Care and Nursing, Gjøvik University College, Gjøvik, Norway. 7Municipality of Bergen, Bergen, Norway. 8Department of Global Public Health and Primary Care, University of Bergen, PO Box 7804N-5018 Bergen, Norway. 9Faculty of Health, Care and Nursing, Norwegian University of Science and Technology (NTNU) in Gjøvik, N-2821 Gjøvik, Norway.

Received: 29 December 2015 Accepted: 23 May 2016
Published online: 01 June 2016

References
1. Gordon AL, Franklin M, Bradshaw L, Logan P, Elliott R, Gladman JR. Health status of UK care home residents: a cohort study. Age Ageing. 2014;43:97–103.
2. Selbaek G, Engedal K, Benths JS, Bergh S. The course of neuropsychiatric symptoms in nursing-home patients with dementia over a 53-month follow-up period. Int Psychogeriatr. 2014;26:681–91.
3. Gaugler JE, Wall MM, Kane RL, Menk JS, Sarsour K, Johnston JA, et al. Does caregiver burden mediate the effects of behavioral disturbances on nursing home admission? Am J Geriatr Psychiatry. 2011;19:497–506.
4. Seitz DP, Gill SS, Hermann N, Brisbin S, Rapoport MJ, Rines J, et al. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Int Psychogeriatr. 2013;25:185–203.
5. Rognstad S, Brekke M, Fetveit A, Spigset O, Wyller TB, Strandø A. The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study. Scand J Prim Health Care. 2009;27:153–9.
6. Food and Drug Administration. Antipsychotics: conventional and atypical 2008. [http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlerts forHumanMedicalProducts/ucm110212.htm]. Accessed 2 June 2015.
7. Nijk RM, Zuiderma SJ, Koopmans RT. Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. Int Psychogeriatr. 2009;21:485–93.
8. Azermai M, Elseviers M, Petrovic M, Van Bortel L, Vander Stichele R. Geriatric drug utilisation of psychotropics in Belgian nursing homes. Hum Psychopharmacol. 2011;26:12–20.
9. Ruths S, Sorensen PH, Kirkevold O, Husebo BS, Kruger K, Halvorsen KH, et al. Trends in psychotropic drug prescribing in Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts. Int J Geriatr Psychiatry. 2013;28:868–76.
10. Boyce RD, Hanlon JT, Karp JK, Kolhe S, Saleh A, Handler SM. A review of the effectiveness of antidepressant medications for depressed nursing home residents. J Am Med Dir Assoc. 2012;13:326–31.
11. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5:245–55.
12. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;3:CD007726.
13. Helvik AS, Engedal K, Benth JS, Selbaek G. Prevalence and Severity of psychiatric symptoms in dementia. Scand J Prim Health Care. 2009;27:153–9.
14. van der Cammen TJ, Rajkumar C, Onder G, Sterke CS, Petrovic M. Drug cessation in complex older adults: time for action. Age Ageing. 2014;43:20–5.
15. Lyketsos CG, Del Campo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–46.
16. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–43.
17. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8:151–7.
18. Coupland C, Dhiman P, Morris R, Arthur A, Barton G, Hippsley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.
19. Bakken MS, Engeland A, Engesæter LB, Ranhoff AH, Hunskar S, Raths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur J Clin Pharmacol. 2014;70:873–80.
20. Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22:843–9.
21. Kirkevold O, Engedal K. Is covert medication in Norwegian nursing homes still a problem? A cross-sectional study. Drugs Aging. 2009;26:333–44.
22. Helvik AS, Engeland K, Benths JS, Selbaek G. Prevalence and Severity of Dementia in Nursing Home Residents. Dement Geriatr Cogn Disord. 2015;40:166–77.
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.
24. Selbaek G, Kirkevold O, Sommer OH, Engedal K. The reliability and validity of the Norwegian version of the Neuropsychiatric Inventory, nursing home version (NPI-NH). Int Psychogeriatr. 2008;20:375–82.
26. Selbaek G, Engedal K. Stability of the factor structure of the Neuropsychiatric Inventory in a 31-month follow-up study of a large sample of nursing-home patients with dementia. Int Psychogeriatr. 2012;24:62–73.

27. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:66–72.

28. Waite L, Grayson D, Jorm AF, Creasey H, Cullen J, Bennett H, et al. Informant-based staging of dementia using the clinical dementia rating. Alzheimer Dis Assoc Disord. 1999;13:34–7.

29. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.

30. Waldman A, Fryman E. Classification in homes for the aged. Geriatric institutional management. New York: Putnam’s; 1964.

31. World Health Organization. ATC/DDD Index 2015. [http://www.whocc.no/atc_ddd_index/]. Accessed 15 Sept 2015.

32. World Health Organization. International statistical classification of diseases and related health problems (ICD-10). 10th ed. Geneva: WHO; 1992.

33. Kleinbaum DG, Klein M, Pryor ER. Logistic regression a self-learning text. 3rd ed. New York: Springer; 2010.

34. Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res. 2006;55:252–8.

35. Olsson J, Bergman A, Carlsten A, Oke T, Bernsten C, Schmidt IK, et al. Quality of drug prescribing in elderly people in nursing homes and special care units for dementia: a cross-sectional computerized pharmacy register analysis. Clin Drug Investig. 2010;30:289–300.

36. Lovheim H, Sandman PO, Kallin K, Karlsson S, Gustafson Y. Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr. 2006;18:173–26.

37. Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behavior. Int Psychogeriatr. 2011;23:1632–9.

38. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4:e006544.

39. Selbaek G, Engedal K, Bergh S. The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review. J Am Med Dir Assoc. 2013;14:161–9.

40. Iden KR, Engedal K, Hjorleifsson S, Ruths S. Prevalence of depression among recently admitted long-term care patients in Norwegian nursing homes: associations with diagnostic workup and use of antidepressants. Dement Geriatr Cogn Disord. 2014;37:154–62.

41. National Institute for Health and Care Excellence: Dementia: supporting people with dementia and their carers in health and social care. 2016. https://www.nice.org.uk/guidance/cg42. Accessed 25 May 2016.

42. Lindesay J, Matthews R, Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry. 2003;18:511–9.

43. Rabins PV, Rovner BW, Rummans TA, Schneider L, Tariot PN. Guideline watch (October 2014): Practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias 2014. [http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/alzheimerwatch.pdf]. Accessed 10 Feb 2015.

44. Ballard C, Corbett A. Dementia: new guidelines on disorders associated with dementia. Nat Rev Neurol. 2012;8:663–4.

45. Gellad WF, Aspinall SL, Handler SM, Stone RA, Castle N, Semla TP, et al. Use of antipsychotics among older residents in VA nursing homes. Med Care. 2012;50:954–60.

46. Helsedirektoratet. Diagnoser i IPLOS-registeret – Et forprosjekt med kommunene Harstad, Stange og Sandefjord (IS-0427). Oslo: Helsedirektoratet; 2014.

47. Halvorsen KH, Granas AG, Engeland A, Ruths S. Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs. Pharmacoeconom Drug Saf. 2012;21:929–36.

48. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065.

Submit your next manuscript to BioMed Central and we will help you at every step:

• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit